GC
BEAM icon

Garde Capital’s Beam Therapeutics BEAM Stock Holding History

Garde Capital’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,200
Closed -$104K – 288
2021
Q3 		$104K Hold
1,200
– – 0.01% 270
2021
Q2 		$154K Buy
+1,200
New +$95.6K 0.02% 225

Other funds holding BEAM

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Garde Capital's BEAM Position: Q4 2021 in Review

Garde Capital sold out of Beam Therapeutics (BEAM) in Q4 2021, closing a stake of 1,200 shares — an estimated $104K sold.

Garde Capital first reported a position in BEAM in Q2 2021 and held it in 2 quarters. The position peaked at $154K in Q2 2021. 232 funds tracked by Wall St. Rank hold BEAM as of Q4 2021.

  • Garde Capital reported no remaining Beam Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Garde Capital sold 1,200 Beam Therapeutics shares in Q4 2021, an estimated $104K.
  • Garde Capital first reported a position in Beam Therapeutics in Q2 2021 and held it in 2 quarters.
  • Garde Capital's Beam Therapeutics position peaked at $154K in Q2 2021.
  • 232 funds tracked by Wall St. Rank held Beam Therapeutics as of Q4 2021.

Based on Garde Capital's 13F filing for Q4 2021, filed 25 Feb 2022.